All posts by psufka

Online rheumatology learning options during the COVID-19 outbreak

1. DermJC discussing biologics during the COVID-19 outbreak

Date: April 1, 2020
Time: 9pm EST (click here to find this in your local time zone)

2. Thomas Jefferson Rheumatology Invitation for Journal Club using Zoom: https://Jefferson.zoom.us/j/7397827851
Friday, April 3, 8:30am Eastern Time (New York time) (click here to find this in your local time zone)
Itinerary as follows: 4 journal articles will be discussed: Please plan for 10-15-minute
presentation for each case. 

  1. Dr. Cathy Lee Ching MD – Case Report on Covid 19 patient with MAS features
  2. Dr. Nandini Setia MD – Epidemiologic features and clinical features of COVID19
  3. Dr. Yvan Maque Acosta MD – Role of Hydroxychloroqine in treatment of COVID19
  4. Dr. Shady Abdelbaki MD – Role of IL-6 Inhibition in treatment of COVID19
    Feel free to ask questions. 
    This is our first-time doing a Zoom presentation so please be patient. Rheumatology training programs around the world must now use Zoom or a similar system for conferences. This gives us the opportunity to share resources. We chose journal club format to start because of the current crisis. In the future we can share speakers, case discussions, journal club, etc. Our vision is that other programs and/or individuals will step forward. Please list proposed activity at least a week in advance. Our programs are on Friday mornings but of course we are all not on the same schedule. So please list time and day of planned conference.

Thank you and let us all use our imagination to not only get through this difficult time but to thrive.
Michele Meltzer, MD
Associate Professor of Medicine
Thomas Jefferson University
Philadelphia, Pa.

Anifrolumab in Lupus: The TULIP-1 & TULIP-2 Trials

Greetings #RheumJC friends!

First, we have an exciting announcement: We’ve teamed up with Healio Rheumatology, who is going to be helping the #RheumJC team with summaries of articles, graphics, and helping to expand the reach of our journal club. We’re greatly looking forward to working with them!

Our next journal club will be Thursday, February 27th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’re going to be discussing the two articles reporting results from the TULIP–1 and TULIP–2 trials, which looked at the use of the type I interferon receptor blocker anifrolumab in systemic lupus erythematosis.

TULIP–1
Healio Rheumatology Summary
The Lancet Rheumatology: Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP–1): a randomised, controlled, phase 3 trial

TULIP–2
Healio Rheumatology Summary
NEJM: Trial of Anifrolumab in Active Systemic Lupus Erythematosus

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Complement Activation in Patients With Probable Lupus and Ability to Predict Progression

Hello everyone!

Our first journal club of 2020 will be Thursday, January 23rd at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the open access article from Arthritis & Rheumatology: Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus.

One of the authors of this article is Dr. Christopher Collins (@RheumPearls), who is also one of the original #RheumJC co-founders, and will be joining us for the journal club session.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Favorite Abstracts from the 2019 ACR Annual Meeting

Our next journal club will be Thursday, December 12th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing our favorite abstracts from the ACR 2019 Annual Meeting, chosen by the #RheumJC team. Feel free to let us know what your favorite abstracts during the session.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Treatment Delays Associated with Prior Authorization

UPDATED DATE & TIME

Our next journal club will be Wednesday, October 23rd at 8:30pm Eastern Time / 7:30pm Central Time (click here to find this in your local time zone).

We’ll be discussing the recently published Arthritis Care & Research article: Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study by Dr. Zachary S. Wallace, et al.

The primary author, Dr. Wallace (@zach_wallace_md), will be joining us for the journal club session, so you won’t want to miss this one.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Gene expression biomarkers to predict response to methotrexate

Our next #RheumJC will be Thursday, June 27th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the Open Access Arthritis & Rheumatology article: Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Nintedanib for Systemic Sclerosis–Associated ILD

Our next #RheumJC will be Thursday, May 30th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the NEJM article: Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Assessing RA Disease Activity using Digital Technology

Our next #RheumJC will be Thursday, April 25th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the Arthritis Care & Research article: Assessing RA Disease Activity with PROMIS Measures using Digital Technology.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Tramadol and Mortality in Osteoarthritis

Our next #RheumJC will be Thursday, March 28th at 9pm Eastern Time / 8pm Central Time (click here to find this in your local time zone).

We’ll be discussing the JAMA article: Association of Tramadol With All-Cause Mortality Among Patients With Osteoarthritis

For some bonus learning, we suggest reading the writeup on the Nephmadness 2019: Pain Region, which includes sections on tramadol as well as opioids, NSAIDs, and GABAnergics.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Ustekinumab in Axial Spondyloarthritis

❄️ Happy February! ☃️

Our next #RheumJC will be Thursday, February 28th at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).

We’ll be discussing the Arthritis & Rheumatology article: Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.